Couto O F M, Dvorchik I, Carr B I
Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pensylvania 15213, USA.
Dig Dis Sci. 2007 Nov;52(11):3285-9. doi: 10.1007/s10620-007-9750-3. Epub 2007 Apr 10.
Most patients with hepatocellular carcinoma (HCC) also have cirrhosis, an independent cause of death. We considered an alternative definition of tumor-related death in patients with HCC and attempted to validate our definition. Two hundred thirty-seven HCC patients were diagnosed, followed, and died over a 12-year period and were evaluated every 2 months, including their last 6 months of life. We defined death by cancer if there was, in the last 6 months of life, a CT scan increase of >25% in the sum of tumor index lesions' cross-sectional areas or new onset of, or increase in, either vascular invasion or metastatic disease (Group 1). Patients with stable cancer were considered to have died from any other cause (Group 2). We found that 135 (57%) patients died from cancer progression (Group 1), whereas 102 (43%) patients did not (Group 2). There was a statistically significant difference between Group 1 and Group 2 patients in percentage with bilobar disease (P = 0.03), more than one tumor (P = 0.01), an increase in AFP (P = 0.04), vascular invasion (P = 0.001), and the presence of metastases (P = 0.01). We conclude that 57% of patients with unresectable HCC died as a direct result of cancer progression, but 43% did not. The latter died from complications of their cirrhosis, including sepsis, GI bleeds, and renal failure.
大多数肝细胞癌(HCC)患者同时患有肝硬化,这是一个独立的死亡原因。我们考虑了HCC患者肿瘤相关死亡的另一种定义,并试图验证我们的定义。在12年期间,对237例HCC患者进行了诊断、随访和死亡情况评估,每2个月进行一次评估,包括他们生命的最后6个月。如果在生命的最后6个月内,CT扫描显示肿瘤指数病变的横截面积总和增加>25%,或者出现新的血管侵犯或转移疾病,或者血管侵犯或转移疾病加重,我们将其定义为死于癌症(第1组)。癌症病情稳定的患者被认为死于任何其他原因(第2组)。我们发现,135例(57%)患者死于癌症进展(第1组),而102例(43%)患者并非如此(第2组)。第1组和第2组患者在双侧病变百分比(P = 0.03)、多个肿瘤(P = 0.01)、甲胎蛋白升高(P = 0.04)、血管侵犯(P = 0.001)以及转移灶存在情况(P = 0.01)方面存在统计学显著差异。我们得出结论,57%的不可切除HCC患者直接死于癌症进展,但43%的患者并非如此。后者死于肝硬化并发症,包括败血症、胃肠道出血和肾衰竭。